Hormonal Intensification Should Start at the Low-risk Stage in Metastatic Prostate Cancer

The treatment landscape for metastatic hormone-sensitive prostate cancer (mHSPC) has dramatically evolved. Monotherapy androgen deprivation therapy (ADT) with testosterone suppression alone is no longer the standard of care as multiple global phase 3 trials of different combinatorial strategies have...

Descripción completa

Detalles Bibliográficos
Autores principales: Jazayeri, Seyed Behzad, Cooley, Lauren Folgosa, Srivastava, Abhishek, Shore, Neal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Open Horizon
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523347/
https://www.ncbi.nlm.nih.gov/pubmed/36186607
http://dx.doi.org/10.1016/j.euros.2022.05.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523347/
https://www.ncbi.nlm.nih.gov/pubmed/36186607
http://dx.doi.org/10.1016/j.euros.2022.05.015

Ejemplares similares